<DOC>
	<DOCNO>NCT01148979</DOCNO>
	<brief_summary>This study aim test effect newly-approved stimulant medication , lisdexamfetamine ( Vyvanse ) , specific residual symptom depression find patient undergoing treatment , partially respond , selective-serotonin reuptake inhibitor ( SSRI ) selective-norepinephrine reuptake inhibitor ( SNRI ) antidepressant . Specifically , investigator hypothesize symptom potentially related deficient dopaminergic activity , lassitude , apathy , reduce positive affect impaired executive function , particular , improve . This protocol design test hypothesis cluster co-occurring residual symptom sometimes find treated depression respond group psychostimulant therapy . The investigator propose measure cluster symptom population residually depressed subject demonstrate , measure effect stimulant therapy cluster , constituent symptom , well measure effect subject ' overall functional impairment , document treatment emergent adverse effect . The investigator hope good understand specific symptoms clinical population likely improve stimulant therapy . The investigator also hope able characterize side effect burden stimulant therapy clinical population .</brief_summary>
	<brief_title>Lisdexamfetamine Dimesylate Residual Symptoms Cognitive Impairment Major Depressive Disorder .</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>1 . Meeting diagnostic criterion major depression present episode illness , currently least mild improvement report ( CGII ≥3 ) continue residual symptom . 2 . A score ≥10 MADRS item 1,2,6,7 8 , ( MADRS Dysphoric Apathy/Retardation factor , Parker et al. , 2003 ) screen randomization . These 5 item : Apparent sadness , Reported sadness , Concentration difficulty , Lassitude , Inability feel . A score ≥3 require least 2 item . 3 . A score 3 4 Clinical Global Impression Severity ( CGIS ) screen randomization . 4 . At randomization subject must receive therapeutic dosage approve SSRI SNRI agent least 8 week , last 4 week constant dosage . 5 . Females Childbearing Potential ( FOCP ) must negative serum beta Human Chorionic Gonadotropin ( BhCG ) pregnancy test screen visit negative urine pregnancy test baseline visit , agree use one follow method birth control : oral contraceptive , contraceptive implant , injectable contraceptive , IUDs , doublebarrier contraception , sexual abstinence vasectomize partner ( ) . 1 . Treatment within 4 week randomization nonSSRI/SNRI antidepressant ( trazodone permit 100 mg HS sleep ) ; antipsychotic agent ; mood stabilizer ; stand benzodiazepine regimen low dos sleep ( ≤ 1 mg lorazepam HS equivalent ) ; stand regimen agent may affect cognitive function ( e.g. , psychostimulants , include modafinil Rmodafinil ) . 2 . Any current past psychotic disorder , Bipolar I II disorder , Current panic disorder , History ADHD , Antisocial Personality Disorder Borderline Personality Disorder , Mental retardation dementing disorder . Covi Anxiety Scale score great Raskin Depression Scale score Screening , exclude subject prominent anxiety depression 3 . MADRS Sleep ( item 4 ) , Appetite ( item 5 ) &gt; 3 screen randomization 4 . Initial insomnia screen adequately control sleep medication ( trazodone 100 mg HS sleep and/or ≤ 1 mg lorazepam HS equivalent ) . 5 . Medical condition might exacerbate Vyvanse treatment , uncontrolled hypertension angina ; condition would make study finding hard interpret , hyperthyroidism 6 . History seizure ( infantile febrile seizure ) , tic disorder , current diagnosis and/or family history Tourette 's Disorder . 7 . Known cardiac structural abnormality condition may affect cardiac performance 8 . Any clinically significant ECG laboratory abnormality Screening 9 . Current abnormal thyroid function , define abnormal TSH Screening ( Treatment stable dose thyroid medication least 3 month permit TSH normal screening ) . 10 . Suicide attempt within past 2 year history homicidal behavior . 11 . MADRS Suicidal thought ( item 10 ) &gt; 4 study visit , patient consider investigator clinical risk suicide time course study . 12. rest sit systolic blood pressure &gt; 149mmHg diastolic blood pressure &gt; 95mmHg . Subjects may monotherapy antihypertensive medication . 13. document allergy , hypersensitivity , intolerance , nonresponsivity methylphenidate amphetamine . 14 . Subject history substance use disorder ( abuse dependence , define DSMIVTR™ ) , exception nicotine dependence , within 6 month prior screen . 15 . Subject glaucoma 16 . Subject take medication central nervous system ( CNS ) effect affect performance , sedate antihistamine decongestant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Cognitive Impairment</keyword>
	<keyword>Partial Response</keyword>
	<keyword>Residual Symptoms</keyword>
</DOC>